News und Analysen

The market had no love for Sarepta Therapeutics (NASDAQ: SRPT) and Teladoc Health (NYSE: TDOC) last year, as both companies lagged broader equities and lost significant market value. This might make

ImmunityBio (NASDAQ:IBRX), which develops immunotherapies for cancers and infectious diseases, closed Wednesday at $6.92, up 6.79%. The stock moved higher as short-sellers considered what to do

Last year was a challenging one for Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech. The company made little clinical progress and, in fact, one of the major data readouts it released was not

For the last three years, the S&P 500 index has generated abnormally high returns thanks to absurd levels of demand for artificial intelligence (AI). In particular, the technology and infrastructure

Explore the exciting world of Insulet (NASDAQ: PODD) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market

Corvus Pharmaceuticals (NASDAQ:CRVS), an immuno-oncology and dermatology drug developer, closed Tuesday at $21.41, up 165.96%. The stock moved higher after Phase 1 soquelitinib data in atopic

ImmunityBio (NASDAQ:IBRX), an immunotherapy and infectious disease drug maker, closed Tuesday at $6.48, up 17.39%. The stock is reacting to reports on FDA end-of-phase discussions for ANKTIVA label

Shares of Rapt Therapeutics (NASDAQ: RAPT) surged on Tuesday after the immunology specialist struck a deal to be acquired by British pharmaceutical leader GSK (NYSE: GSK) for $2.2 billion.

By the

There's no two ways about it. Nvidia has been the centerpiece of the artificial intelligence (AI) revolution thus far. Its processors are the heart and soul of most of the planet's AI data centers

For the last three years, there has been no company in the semiconductor industry as dominant as Nvidia (NASDAQ: NVDA). The company kick-started the artificial intelligence (AI) revolution with its

Investors in biotechnology company Viking Therapeutics (NASDAQ: VKTX) had a rollercoaster ride in 2025, driven by clinical trial data, or rather, the perception of the clinical trial data. Let's

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD), Riot Platforms (NASDAQ: RIOT), and other AI stocks. To learn more, check out the short video, consider

There's a boom going on in much of the U.S., and it's not just tied to technology. Housing shortages have spurred residential homebuilding activity, particularly in fast-growing areas like the Sun

Explore the exciting world of Halozyme Therapeutics (NASDAQ: HALO) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights

Pfizer (NYSE: PFE) is in the Wall Street doghouse. It is currently viewed as an also-ran in the drug sector, lagging far behind peers like Eli Lilly (NYSE: LLY) in various categories, including the

2026 is shaping up to be another fantastic year for the stock market, especially with the amount of artificial intelligence (AI) spending going on. I think there are several stocks bound to rocket

Broader equities almost always deliver positive returns over the span of a decade. That's been the case for over 100 years, other than a few 10-year periods that were rocked by significant economic

The days when you had to rely on two human beings yelling at each other across a trading floor to buy 100 shares of stock are long gone, and the electronic trading platforms that have largely

Healthcare-focused investors may be disappointed to learn that the sector underperformed the broader market last year. However, they might also appreciate the fact that there are plenty of stocks in

Medtronic (NYSE: MDT) is coming off a strong year. The company performed well in 2025, despite some threats to its business, including the impact of tariffs on its operations.

As 2026 begins, the

When it comes to leading semiconductor stocks, most investors probably don't bother looking past Nvidia, Advanced Micro Devices, and Broadcom. These three powerhouses dominate the market for AI

AbbVie (NYSE: ABBV) has delivered excellent returns over the past decade. It experienced a slight slowdown in recent years as it navigated the loss of patent exclusivity for its former best-selling

Shares of the iShares Semiconductor ETF (NASDAQ: SOXX) were soaring last year, reflecting the continuing AI boom, and gains in top members like Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ:

Artificial intelligence (AI) stocks soared last year, and exchange-traded funds (ETFs) that focus on AI stocks jumped as well.

One of those ETFs was the Global X Artificial Intelligence and

It's easy to hold a growth stock and feel good about it when that asset is outperforming the S&P 500. However, corrections can test an investor's patience and cause people to exit great companies